Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha

G. Barbaro; G. Di Lorenzo; M. Soldini; G. Gianeaspro; A. Pellicelli; B. Grisorio; G. Barbarini; F. De Rosa; F. Cadario; D. Capelli; G. Filice; A. Paiano; G. Belloni; L. Ferrari; G. Gualandi; I. Poltronieri; A. Barelli; P. Rocchetto; P. Del Poggio; G. Bellomo; G. Calleri; G. Cariti; L. Fruttaldo; F. Mongiò; G. Rizzo; M. Annese; G. Scotto; D. Bacca; R. Francavilla

doi:10.1080/003655299750025426

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha

G. Barbaro, G. Di Lorenzo, M. Soldini, G. Gianeaspro, A. Pellicelli, B. Grisorio, G. Barbarini, F. De Rosa, F. Cadario, D. Capelli, G. Filice, A. Paiano, G. Belloni, L. Ferrari, G. Gualandi, I. Poltronieri, A. Barelli, P. Rocchetto, P. Del Poggio, G. BellomoG. Calleri, G. Cariti, L. Fruttaldo, F. Mongiò, G. Rizzo, M. Annese, G. Scotto, D. Bacca, R. Francavilla

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Little is known about the therapeutic role of intravenous interferon-beta in chronic hepatitis C patients unresponsive to a previous treatment with interferon-alpha. Methods: Two hundred interferon alpha non- responders were randomized to receive either intravenous recombinant interferon-beta or interferon-alpha-2b and ribavirin for 12 weeks. The responders in both groups were followed up for a further 48 weeks. Results: At week 12 a biochemical and virologic response was documented in 42% of the patients treated with interferon-beta and in 22% of the patients treated with combination therapy. A sustained response was observed in 21% of the patients treated with interferon-beta and in 13% of those treated with combination therapy, with similar differences on intention-to-treat analysis. Conclusions: Short-term treatment with intravenous interferon-beta seems to offer a chance for sustained response in a subset of interferon-alpha non- responders. The role of long-term therapy in these patients still remains to be explored.

Original language	English
Pages (from-to)	928-933
Number of pages	6
Journal	Scandinavian Journal of Gastroenterology
Volume	34
Issue number	9
DOIs	https://doi.org/10.1080/003655299750025426
Publication status	Published - 1999

Keywords

Chronic hepatitis C
Interferon-alpha
Interferon-beta
Ribavirin

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1080/003655299750025426

Fingerprint Dive into the research topics of 'Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha'. Together they form a unique fingerprint.

Cite this

Barbaro, G., Di Lorenzo, G., Soldini, M., Gianeaspro, G., Pellicelli, A., Grisorio, B., Barbarini, G., De Rosa, F., Cadario, F., Capelli, D., Filice, G., Paiano, A., Belloni, G., Ferrari, L., Gualandi, G., Poltronieri, I., Barelli, A., Rocchetto, P., Del Poggio, P., ... Francavilla, R. (1999). Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scandinavian Journal of Gastroenterology, 34(9), 928-933. https://doi.org/10.1080/003655299750025426

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. / Barbaro, G.; Di Lorenzo, G.; Soldini, M.; Gianeaspro, G.; Pellicelli, A.; Grisorio, B.; Barbarini, G.; De Rosa, F.; Cadario, F.; Capelli, D.; Filice, G.; Paiano, A.; Belloni, G.; Ferrari, L.; Gualandi, G.; Poltronieri, I.; Barelli, A.; Rocchetto, P.; Del Poggio, P.; Bellomo, G.; Calleri, G.; Cariti, G.; Fruttaldo, L.; Mongiò, F.; Rizzo, G.; Annese, M.; Scotto, G.; Bacca, D.; Francavilla, R.

In: Scandinavian Journal of Gastroenterology, Vol. 34, No. 9, 1999, p. 928-933.

Research output: Contribution to journal › Article › peer-review

Barbaro, G, Di Lorenzo, G, Soldini, M, Gianeaspro, G, Pellicelli, A, Grisorio, B, Barbarini, G, De Rosa, F, Cadario, F, Capelli, D, Filice, G, Paiano, A, Belloni, G, Ferrari, L, Gualandi, G, Poltronieri, I, Barelli, A, Rocchetto, P, Del Poggio, P, Bellomo, G, Calleri, G, Cariti, G, Fruttaldo, L, Mongiò, F, Rizzo, G, Annese, M, Scotto, G, Bacca, D & Francavilla, R 1999, 'Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha', Scandinavian Journal of Gastroenterology, vol. 34, no. 9, pp. 928-933. https://doi.org/10.1080/003655299750025426

Barbaro G, Di Lorenzo G, Soldini M, Gianeaspro G, Pellicelli A, Grisorio B et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scandinavian Journal of Gastroenterology. 1999;34(9):928-933. https://doi.org/10.1080/003655299750025426

Barbaro, G. ; Di Lorenzo, G. ; Soldini, M. ; Gianeaspro, G. ; Pellicelli, A. ; Grisorio, B. ; Barbarini, G. ; De Rosa, F. ; Cadario, F. ; Capelli, D. ; Filice, G. ; Paiano, A. ; Belloni, G. ; Ferrari, L. ; Gualandi, G. ; Poltronieri, I. ; Barelli, A. ; Rocchetto, P. ; Del Poggio, P. ; Bellomo, G. ; Calleri, G. ; Cariti, G. ; Fruttaldo, L. ; Mongiò, F. ; Rizzo, G. ; Annese, M. ; Scotto, G. ; Bacca, D. ; Francavilla, R. / Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. In: Scandinavian Journal of Gastroenterology. 1999 ; Vol. 34, No. 9. pp. 928-933.

@article{126fb7b84cfa4cde8d36f9f93466cf22,

title = "Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha",

abstract = "Background: Little is known about the therapeutic role of intravenous interferon-beta in chronic hepatitis C patients unresponsive to a previous treatment with interferon-alpha. Methods: Two hundred interferon alpha non- responders were randomized to receive either intravenous recombinant interferon-beta or interferon-alpha-2b and ribavirin for 12 weeks. The responders in both groups were followed up for a further 48 weeks. Results: At week 12 a biochemical and virologic response was documented in 42% of the patients treated with interferon-beta and in 22% of the patients treated with combination therapy. A sustained response was observed in 21% of the patients treated with interferon-beta and in 13% of those treated with combination therapy, with similar differences on intention-to-treat analysis. Conclusions: Short-term treatment with intravenous interferon-beta seems to offer a chance for sustained response in a subset of interferon-alpha non- responders. The role of long-term therapy in these patients still remains to be explored.",

keywords = "Chronic hepatitis C, Interferon-alpha, Interferon-beta, Ribavirin",

author = "G. Barbaro and {Di Lorenzo}, G. and M. Soldini and G. Gianeaspro and A. Pellicelli and B. Grisorio and G. Barbarini and {De Rosa}, F. and F. Cadario and D. Capelli and G. Filice and A. Paiano and G. Belloni and L. Ferrari and G. Gualandi and I. Poltronieri and A. Barelli and P. Rocchetto and {Del Poggio}, P. and G. Bellomo and G. Calleri and G. Cariti and L. Fruttaldo and F. Mongi{\`o} and G. Rizzo and M. Annese and G. Scotto and D. Bacca and R. Francavilla",

year = "1999",

doi = "10.1080/003655299750025426",

language = "English",

volume = "34",

pages = "928--933",

journal = "Scandinavian Journal of Gastroenterology",

issn = "0036-5521",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha

AU - Barbaro, G.

AU - Di Lorenzo, G.

AU - Soldini, M.

AU - Gianeaspro, G.

AU - Pellicelli, A.

AU - Grisorio, B.

AU - Barbarini, G.

AU - De Rosa, F.

AU - Cadario, F.

AU - Capelli, D.

AU - Filice, G.

AU - Paiano, A.

AU - Belloni, G.

AU - Ferrari, L.

AU - Gualandi, G.

AU - Poltronieri, I.

AU - Barelli, A.

AU - Rocchetto, P.

AU - Del Poggio, P.

AU - Bellomo, G.

AU - Calleri, G.

AU - Cariti, G.

AU - Fruttaldo, L.

AU - Mongiò, F.

AU - Rizzo, G.

AU - Annese, M.

AU - Scotto, G.

AU - Bacca, D.

AU - Francavilla, R.

PY - 1999

Y1 - 1999

N2 - Background: Little is known about the therapeutic role of intravenous interferon-beta in chronic hepatitis C patients unresponsive to a previous treatment with interferon-alpha. Methods: Two hundred interferon alpha non- responders were randomized to receive either intravenous recombinant interferon-beta or interferon-alpha-2b and ribavirin for 12 weeks. The responders in both groups were followed up for a further 48 weeks. Results: At week 12 a biochemical and virologic response was documented in 42% of the patients treated with interferon-beta and in 22% of the patients treated with combination therapy. A sustained response was observed in 21% of the patients treated with interferon-beta and in 13% of those treated with combination therapy, with similar differences on intention-to-treat analysis. Conclusions: Short-term treatment with intravenous interferon-beta seems to offer a chance for sustained response in a subset of interferon-alpha non- responders. The role of long-term therapy in these patients still remains to be explored.

AB - Background: Little is known about the therapeutic role of intravenous interferon-beta in chronic hepatitis C patients unresponsive to a previous treatment with interferon-alpha. Methods: Two hundred interferon alpha non- responders were randomized to receive either intravenous recombinant interferon-beta or interferon-alpha-2b and ribavirin for 12 weeks. The responders in both groups were followed up for a further 48 weeks. Results: At week 12 a biochemical and virologic response was documented in 42% of the patients treated with interferon-beta and in 22% of the patients treated with combination therapy. A sustained response was observed in 21% of the patients treated with interferon-beta and in 13% of those treated with combination therapy, with similar differences on intention-to-treat analysis. Conclusions: Short-term treatment with intravenous interferon-beta seems to offer a chance for sustained response in a subset of interferon-alpha non- responders. The role of long-term therapy in these patients still remains to be explored.

KW - Chronic hepatitis C

KW - Interferon-alpha

KW - Interferon-beta

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=0032888775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032888775&partnerID=8YFLogxK

U2 - 10.1080/003655299750025426

DO - 10.1080/003655299750025426

M3 - Article

C2 - 10522614

AN - SCOPUS:0032888775

VL - 34

SP - 928

EP - 933

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 9

ER -